Infliximab dramatically clears severe psoriasis

Article

New Orleans - The experience of a teenage girl treated successfully with infliximab (Remicade) for severe, recalcitrant psoriasis of her hands and feet indicates the value of the TNF-alpha chimeric monoclonal antibody as a therapeutic option for psoriasis.

Related Videos
Related Content

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Botulinum Toxin Lacks Significant Effect in Seborrheic Dermatitis, Study Says

September 26th 2023

Severe Psoriasis Associated With Higher Risk of Heart Disease

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.